TX-PLANVIEW
21.7.2021 15:04:13 CEST | Business Wire | Press release
Planview , a global leader in Portfolio Management and Work Management solutions, today reported record revenue and bookings in Q2 2021 continuing a trend of strong momentum and growth in 2021. Bookings for the second quarter of the year were at a record high, and total bookings in the first half of 2021 increased 40 percent year-over-year on a consolidated basis. The bookings growth in the second quarter of 2021 was driven by both new customer additions and customer expansions across financial services, pharmaceutical, and manufacturing industries. Additionally, total software annual recurring revenue (ARR) for Q2 increased to an all-time high in excess of $300 million.
“Our customers are grappling with change across multiple vectors: from evolving market dynamics, fierce competition, and changing customer expectations, to new business models, shifting company strategies and entirely new ways of working,” said Razat Gaurav, chief executive officer, Planview. “The key to turning these changes into opportunities is a company’s ability to adapt, be agile, and constantly transform. Planview’s Portfolio and Work Management solutions enable customers to embrace change without losing sight of key priorities or company strategy.”
Q2 2021 Customer Momentum
Planview’s momentum in Q2 has been driven by key customer wins and expansions. Throughout the quarter, the company added 112 net new customers, reaching a total of 225 net new customers in 2021. Customers who selected or extended their footprint with Planview during the quarter include: Global Payments, KBI Biopharma, Lonza, and Rosenberger Hochfrequenztechnik GmbH & Co.
“KBI Biopharma prides itself on high technical standards and scientific rigor, and our ability to tailor our contract development and manufacturing organization (CDMO) offerings to meet the individual needs of each and every partner,” said Dirk Lange, President and CEO, KBI Biopharma. “We chose to invest in Planview software because it enables the precision and insight that we need to optimally structure and resource our client engagements. We are looking forward to our continued growth with the support of this platform to help advance lifesaving therapeutics to patients in need.”
Planview Leadership
Following the completion of the integration of Clarizen and Changepoint into Planview , the company also announced its go-forward leadership team :
- Louise K. Allen, Chief Product Officer
- Todd Watts, Chief Customer Officer
- Matt Zilli, Chief Revenue Officer
- Cameron van Orman, Chief Strategy & Marketing Officer
- Jay Nelson, Chief People Officer
- Beth Weeks, Chief Information Officer and Vice President, Cloud Operations
- Rob Reesor, Chief Technology Officer and SVP, Product Development
- Chris Carsen, Chief Legal Officer
“I’m excited to support this world-class leadership team as we scale up our business,” said Gaurav. “Our opportunity to enable digital transformation and reimagine the future of connected work in the enterprise is now. We can only fulfill this massive value potential by continuing to be very committed to our core values underpinned by product innovations, customer and employee success.”
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions enable organizations to navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 1,000 employees supporting 4,500 customers and 1.3 million users worldwide. For more information, visit: www.planview.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005554/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JTB to Acquire Asian DMC Leader EXO Travel for Accelerated Global Growth18.6.2026 04:00:00 CEST | Press release
— Advancing JTB's “Departing Globally, Arriving Globally” Vision — JTB Corp. today announced that it has reached an agreement to acquire all the shares of All Wise Holdings Pte. Ltd., the operator of Bangkok-based EXO Travel Group, a leading Destination Management Companies (DMCs) in Asia. The acquisition will be made through a JTB group company in the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106801/en/ EXO Travel operates in the B2B market, primarily across Asia Pacific. For over 30 years, it has consistently maintained high customer satisfaction based on trust, achievements and high-quality service. The company has a strong brand presence in the affluent markets of Europe, North America and Australia, where the trust of partner companies contributes significantly to its value. Additionally, EXO Travel leverages its extensive network of destinations in Asia Pacific to develop strong products
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody18.6.2026 01:01:00 CEST | Press release
The companies have entered into a multi-year research collaboration, option and licensing agreement in which LabGenius Therapeutics will leverage its AI/ML-driven antibody discovery platform,EVA™, to design and engineer next-generation multispecifics with enhanced therapeutic properties LabGenius Therapeutics will receive an undisclosed upfront payment and potential early milestones, plus, if the option is exercised, potential triple-digit million clinical, regulatory, and commercial milestones, along with royalties on net sales LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together,
Joe Vernachio Named President of SOREL18.6.2026 00:00:00 CEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Joe Vernachio will be the next President of SOREL. Founded in 1962, SOREL is a leader in functional and lifestyle footwear that can be worn anywhere from the tundra to the streets of New York City. “We’re excited to welcome Joe Vernachio back to the Columbia Sportswear family,” said Tim Boyle, CEO and Chair of the Board. “Joe is a terrific leader who can build on the great work, talent and momentum in place at SOREL.” Mr. Vernachio led the Mountain Hardwear brand for several years, until he left to become the COO and ultimately, the CEO of Allbirds. His background also includes time as Global Vice President for Product and Operations at The North Face, and key roles at Nike, Spyder, Roots, Calvin Klein and Patagonia. “Joe is a consumer‑focused, collaborative leader with a deep passion for product and brand storytelling. His energy, experti
Venture Global and EnBW Announce New LNG Purchase Agreements17.6.2026 22:30:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and EnBW announced the execution of new, binding agreements for the purchase of approximately 0.82 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for approximately five years commencing in 2026, to be supplied from Venture Global’s portfolio. The new agreements add to the existing long-term sales and purchase agreements (SPAs) between Venture Global and EnBW for 2 MTPA for 20 years. “As one of Germany’s top LNG suppliers, Venture Global is proud to strengthen our partnership with EnBW and support the region’s energy security with a reliable supply of LNG,” said Venture Global CEO Mike Sabel. “The new mid-term agreements build on our strong, long-standing relationship with EnBW and reflects our commitment to meeting our customers’ evolving energy needs. Our dynamic marketing platform uniquely positions us to provide supply solutions across the short, medium, and long term.” About Venture Global Venture Globa
Kinaxis Announces Results of Voting at Annual and Special Meeting of Shareholders17.6.2026 22:05:00 CEST | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, received approval for all resolutions put forward to shareholders at today’s Annual and Special Meeting of Shareholders (the “Meeting”), as detailed in the Company’s management information circular dated May 5, 2026 (the “Circular”). 1. Election of Directors Shareholders voted to elect all eight directors nominated to the Kinaxis board, to hold office until the close of the next annual meeting of shareholders of the Company or until their successors are elected or appointed. Name of Nominee Total Number of Votes For Percentage of Votes For Total Number of Votes Against Percentage of Votes Against Razat Gaurav 21,870,163 99.01% 219,468 0.99% Robert Courteau 20,882,945 94.54% 1,206,685 5.46% Gillian (Jill) Denham 21,474,486 97.22% 615,143 2.78% José Alberto Duarte 21,699,181 98.23% 390,448 1.77% Lynn Loewen 21,952,244 99.38% 137,387 0.62% Angel Mendez 21,410,402 96
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom